New schedule of bevacizumab/paclitaxel as first‐line therapy for metastatic HER2‐negative breast cancer in a real‐life setting

Angiogenesis plays an essential role in the growth and progression of breast cancer. This observational single center study evaluated the efficacy and safety of a new weekly schedule of bevacizumab/paclitaxel combination in the first‐line treatment of unselected, HER2‐negative, metastatic breast can...

Descripción completa

Detalles Bibliográficos
Autores principales: Cannita, Katia, Paradisi, Stefania, Cocciolone, Valentina, Bafile, Alberto, Rinaldi, Lucia, Irelli, Azzurra, Lanfiuti Baldi, Paola, Zugaro, Luigi, Manetta, Rosa, Alesse, Edoardo, Ricevuto, Enrico, Ficorella, Corrado
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5055157/
https://www.ncbi.nlm.nih.gov/pubmed/27416882
http://dx.doi.org/10.1002/cam4.803

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5055157/
https://www.ncbi.nlm.nih.gov/pubmed/27416882
http://dx.doi.org/10.1002/cam4.803

Ejemplares similares